Literature DB >> 34472654

Improving the prediction of long-term readmission and mortality using a novel biomarker panel.

Jeremiah R Brown1,2, Devin M Parker1, Meagan E Stabler1, Marshall L Jacobs3, Jeffrey P Jacobs4, Allen D Everett5, Kevin W Lobdell6, Moritz C Wyler von Ballmoos7, Heather Thiessen-Philbrook8, Chirag Parikh8, Todd Mackenzie2, Anthony DiScipio9, David Malenka9, Michael E Matheny10, Alexander Turchin11, Donald S Likosky12.   

Abstract

OBJECTIVE: Several short-term readmission and mortality prediction models have been developed using clinical risk factors or biomarkers among patients undergoing coronary artery bypass graft (CABG) surgery. The use of biomarkers for long-term prediction of readmission and mortality is less well understood. Given the established association of cardiac biomarkers with short-term adverse outcomes, we hypothesized that 5-year prediction of readmission or mortality may be significantly improved using cardiac biomarkers.
MATERIALS AND METHODS: Plasma biomarkers from 1149 patients discharged alive after isolated CABG surgery from eight medical centers were measured in a cohort from the Northern New England Cardiovascular Disease Study Group between 2004 and 2007. We assessed the added predictive value of a biomarker panel with a clinical model against the clinical model alone and compared the model discrimination using the area under the receiver operating characteristic (AUROC) curves.
RESULTS: In our cohort, 461 (40%) patients were readmitted or died within 5 years. Long-term outcomes were predicted by applying the STS ASCERT clinical model with an AUROC of 0.69. The biomarker panel with the clinical model resulted in a significantly improved AUROC of 0.74 (p value <.0001). Across 5 years, the hazard ratio for patients in the second to fifth quintile predicted probabilities from the biomarker augmented STS ASCERT model ranged from 2.2 to 7.9 (p values <.001).
CONCLUSIONS: We report that a panel of biomarkers significantly improved prediction of long-term readmission or mortality risk following CABG surgery. Our findings suggest biomarkers help clinical care teams better assess the long-term risk of readmission or mortality.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  CABG; biomarkers; cardiac surgery; risk prediction

Mesh:

Substances:

Year:  2021        PMID: 34472654      PMCID: PMC8560027          DOI: 10.1111/jocs.15954

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.778


  34 in total

Review 1.  ST2: a novel biomarker for heart failure.

Authors:  Anju Bhardwaj; James L Januzzi
Journal:  Expert Rev Mol Diagn       Date:  2010-05       Impact factor: 5.225

2.  Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery.

Authors:  Chirag R Parikh; Steven G Coca; Heather Thiessen-Philbrook; Michael G Shlipak; Jay L Koyner; Zhu Wang; Charles L Edelstein; Prasad Devarajan; Uptal D Patel; Michael Zappitelli; Catherine D Krawczeski; Cary S Passik; Madhav Swaminathan; Amit X Garg
Journal:  J Am Soc Nephrol       Date:  2011-08-11       Impact factor: 10.121

3.  Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.

Authors:  Roland R van Kimmenade; James L Januzzi; Patrick T Ellinor; Umesh C Sharma; Jaap A Bakker; Adrian F Low; Abelardo Martinez; Harry J Crijns; Calum A MacRae; Paul P Menheere; Yigal M Pinto
Journal:  J Am Coll Cardiol       Date:  2006-08-28       Impact factor: 24.094

4.  Impact of Multivessel Coronary Artery Disease With Versus Without Left Main Coronary Artery Disease on Long-Term Mortality After Coronary Bypass Grafting Versus Drug-Eluting Stent Implantation.

Authors:  Mineok Chang; Cheol Whan Lee; Jung-Min Ahn; Rafael Cavalcante; Yohei Sotomi; Yoshinobu Onuma; Duk-Woo Park; Soo-Jin Kang; Seung-Whan Lee; Young-Hak Kim; Seong-Wook Park; Patrick W Serruys; Seung-Jung Park
Journal:  Am J Cardiol       Date:  2016-10-08       Impact factor: 2.778

5.  30-day readmissions after coronary artery bypass graft surgery in New York State.

Authors:  Edward L Hannan; Ye Zhong; Stephen J Lahey; Alfred T Culliford; Jeffrey P Gold; Craig R Smith; Robert S D Higgins; Desmond Jordan; Andrew Wechsler
Journal:  JACC Cardiovasc Interv       Date:  2011-05       Impact factor: 11.195

6.  Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery.

Authors:  Ryan Hutfless; Radmila Kazanegra; Michael Madani; Meenakshi Awasthi Bhalla; Alisi Tulua-Tata; Amelia Chen; Paul Clopton; Cherimarie James; Albert Chiu; Alan S Maisel
Journal:  J Am Coll Cardiol       Date:  2004-05-19       Impact factor: 24.094

7.  Cystatin C blood level as a risk factor for death after heart surgery.

Authors:  Didier Ledoux; Mehran Monchi; Jean-Paul Chapelle; Pierre Damas
Journal:  Eur Heart J       Date:  2007-07-07       Impact factor: 29.983

8.  Utility of Biomarkers to Improve Prediction of Readmission or Mortality After Cardiac Surgery.

Authors:  Jeremiah R Brown; Jeffrey P Jacobs; Shama S Alam; Heather Thiessen-Philbrook; Allen Everett; Donald S Likosky; Kevin Lobdell; Moritz C Wyler von Ballmoos; Devin M Parker; Amit X Garg; Todd Mackenzie; Marshall L Jacobs; Chirag R Parikh
Journal:  Ann Thorac Surg       Date:  2018-08-04       Impact factor: 4.330

9.  Predictors and outcome of ICU readmission after cardiac surgery.

Authors:  J Litmathe; M Kurt; P Feindt; E Gams; U Boeken
Journal:  Thorac Cardiovasc Surg       Date:  2009-09-30       Impact factor: 1.827

10.  Influence of preoperative serum N-terminal pro-brain type natriuretic peptide on the postoperative outcome and survival rates of coronary artery bypass patients.

Authors:  Thomas Schachner; Dominik Wiedemann; Hannes Fetz; Guenther Laufer; Alfred Kocher; Nikolaos Bonaros
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.